Foghorn Therapeutics (FHTX) Retained Earnings (2019 - 2026)

Foghorn Therapeutics' Retained Earnings history runs 8 years deep, the most recent figure standing at -$133000.0 for Q1 2026.

• On a quarterly basis, Retained Earnings fell 1050.0% year-over-year to -$133000.0 in Q1 2026; TTM through Mar 2026 was -$133000.0, a 1050.0% decrease from a year earlier, with the FY2025 full-year figure at $24000.0, down 100.0% from the prior year.
• Retained Earnings fell to -$133000.0 in Q1 2026 per FHTX's latest filing, from $24000.0 in the prior quarter.
• Across five years, Retained Earnings topped out at $512.5 million in Q4 2024 and bottomed at -$610.8 million in Q3 2025.
• The 5-year median for Retained Earnings is -$2.9 million (2023), against an average of -$86.9 million.
• Across the five-year window, Retained Earnings surged 242.75% in 2022 and sank 13481.06% in 2023, its largest moves.
• Year by year, Retained Earnings stood at $377.2 million in 2022, then advanced by 4.76% to $395.2 million in 2023, then advanced by 29.69% to $512.5 million in 2024, then sank by 100.0% to $24000.0 in 2025, then sank by 654.17% to -$133000.0 in 2026.
• Per Business Quant, the three latest FHTX Retained Earnings figures stand at -$133000.0 (Q1 2026), $24000.0 (Q4 2025), and -$610.8 million (Q3 2025).